SCHEMBL4119154

SCHEMBL4119154

COCc1ccc(NC(=O)Nc2ccc(C)c(C)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.62
CDK8 P49336 1/20 0.62
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HTT P42858 1/20 0.59
POLB P06746 2/20 0.54
ALDH1A1 P00352 2/20 0.54
TSHR P16473 1/20 0.54
RECQL P46063 1/20 0.54
RAB9A P51151 6/20 0.51
NPC1 O15118 3/20 0.50
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NTRK1 P04629 1/20 0.49
CNR1 P21554 1/20 0.49
GBA1 P04062 1/20 0.49
TP53 P04637 1/20 0.49
SAE1 Q9UBE0 2/20 0.49
UBA2 Q9UBT2 2/20 0.49
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119200 0.87 NPC1 (0.53) CCNCCDK8MEN1KMT2AHTT
SCHEMBL4111129 0.84 NPC1 (0.60) MEN1KMT2APOLBALDH1A1RAB9A
SCHEMBL4111863 0.83 CCNC (0.67) CCNCCDK8MEN1KMT2AHTT
SCHEMBL4112221 0.81 RAB9A (0.63) MEN1KMT2AHTTPOLBRAB9A
SCHEMBL4117921 0.80 CCNC (0.63) CCNCCDK8MEN1KMT2AHTT
SCHEMBL4112869 0.80 CCNC (0.63) CCNCCDK8MEN1KMT2AHTT
SCHEMBL4113109 0.80 ALDH1A1 (0.56) MEN1KMT2AHTTPOLBALDH1A1
SCHEMBL4118094 0.80 MAPT (0.75) MEN1KMT2AHTTPOLBTSHR
SCHEMBL4105835 0.80 SAE1 (0.76) MEN1KMT2APOLBTSHRRAB9A
SCHEMBL4124272 0.79 MAPT (0.49) MEN1KMT2AHTTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 CCNC 1067/4885CDK8 1510/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.